Showing results (851-860 of 6,303) with videos related to

Sort By:
Pageof 631
Diabetes, Obesity & Metabolism|December 30, 2020
A decrease in plasma glucose levels is required for increased endogenous glucose production with a single administration of a sodium-glucose co-transporter-2 inhibitor tofogliflozinNozomu Yamasaki, Yoshifumi Tamura, Hideyoshi Kaga, et al.
Diabetes, Obesity & Metabolism|December 28, 2020
A model-based approach to investigating the relationship between glucose-insulin dynamics and dapagliflozin treatment effect in patients with type 2 diabetesMillie Shah, Leonid Stolbov, Tatiana Yakovleva, et al.
Diabetes, Obesity & Metabolism|October 21, 2020
Cerebral effects of glucagon-like peptide-1 receptor blockade before and after Roux-en-Y gastric bypass surgery in obese women: A proof-of-concept resting-state functional MRI studyEelco van Duinkerken, Gabriel Bernardes, Liselotte van Bloemendaal, et al.
Diabetes, Obesity & Metabolism|December 3, 2020
Prediction of heart failure outcomes in patients with type 2 diabetes mellitus: Validation of the Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes (TRS-HFDM ) in patients in the ACCORD trialMalik Elharram, João Pedro Ferreira, Thao Huynh, et al.
Diabetes, Obesity & Metabolism|December 3, 2020
Association of weight loss and weight loss maintenance following diabetes diagnosis by screening and incidence of cardiovascular disease and all-cause mortality: An observational analysis of the ADDITION-Europe trialJean Strelitz, Stephen J Sharp, Kamlesh Khunti, et al.
Diabetes, Obesity & Metabolism|October 29, 2020
Antidiabetic medication use in commercially insured children and adolescents in the United States from 2004 to 2019Jenny W Sun, Sonia Hernández-Díaz, Florence T Bourgeois, et al.
Diabetes, Obesity & Metabolism|December 8, 2020
Weight loss-induced increase in fasting ghrelin concentration is a predictor of weight regain: Evidence from the Diabetes Remission Clinical Trial (DiRECT)George Thom, Alasdair McIntosh, Claudia-Martina Messow, et al.
Diabetes, Obesity & Metabolism|December 8, 2020
Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trialsCarine Beysen, Patricia Schroeder, Eric Wu, et al.
Diabetes, Obesity & Metabolism|October 20, 2022
Eight-year trends in obesity-related complications and health care cost progression in a US population with obesity: A retrospective cohort studyMarc Evans, Vamshi Ruthwik Anupindi, Mitch DeKoven, et al.
Diabetes, Obesity & Metabolism|October 6, 2022
Impact of iron supplementation on gestational diabetes mellitus: A literature reviewLulu Liu, Feng Yan, Hongyuan Yan, et al.
Pageof 631